HUP0103578A3 - Method for down-regulating osteoprotegerin ligand activity - Google Patents

Method for down-regulating osteoprotegerin ligand activity

Info

Publication number
HUP0103578A3
HUP0103578A3 HU0103578A HUP0103578A HUP0103578A3 HU P0103578 A3 HUP0103578 A3 HU P0103578A3 HU 0103578 A HU0103578 A HU 0103578A HU P0103578 A HUP0103578 A HU P0103578A HU P0103578 A3 HUP0103578 A3 HU P0103578A3
Authority
HU
Hungary
Prior art keywords
ligand activity
osteoprotegerin ligand
regulating
regulating osteoprotegerin
activity
Prior art date
Application number
HU0103578A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of HUP0103578A2 publication Critical patent/HUP0103578A2/hu
Publication of HUP0103578A3 publication Critical patent/HUP0103578A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
HU0103578A 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity HUP0103578A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
PCT/DK1999/000481 WO2000015807A1 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Publications (2)

Publication Number Publication Date
HUP0103578A2 HUP0103578A2 (hu) 2002-01-28
HUP0103578A3 true HUP0103578A3 (en) 2005-11-28

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103578A HUP0103578A3 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Country Status (24)

Country Link
US (2) US6645500B1 (cg-RX-API-DMAC7.html)
EP (1) EP1114166B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002525060A (cg-RX-API-DMAC7.html)
KR (1) KR100671036B1 (cg-RX-API-DMAC7.html)
CN (1) CN1318105A (cg-RX-API-DMAC7.html)
AT (1) ATE291628T1 (cg-RX-API-DMAC7.html)
AU (1) AU754971B2 (cg-RX-API-DMAC7.html)
CA (1) CA2343654A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2001789A3 (cg-RX-API-DMAC7.html)
DE (1) DE69924392T2 (cg-RX-API-DMAC7.html)
EE (1) EE200100149A (cg-RX-API-DMAC7.html)
ES (1) ES2239457T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040261A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010188A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0103578A3 (cg-RX-API-DMAC7.html)
ID (1) ID28386A (cg-RX-API-DMAC7.html)
IL (2) IL141588A0 (cg-RX-API-DMAC7.html)
NO (1) NO20011304L (cg-RX-API-DMAC7.html)
NZ (1) NZ510508A (cg-RX-API-DMAC7.html)
PL (1) PL196790B1 (cg-RX-API-DMAC7.html)
PT (1) PT1114166E (cg-RX-API-DMAC7.html)
SK (1) SK3062001A3 (cg-RX-API-DMAC7.html)
TR (1) TR200100737T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000015807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CA2647796A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Method of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU7615600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
HRP20020721B1 (en) * 2000-02-21 2012-04-30 H. Lundbeck A/S Novel method for down-regulation of amyloid
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2001062932A1 (en) * 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
AU2001266604A1 (en) * 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002024228A1 (fr) * 2000-09-21 2002-03-28 Center For Advanced Science And Technology Incubation, Ltd. Méthode de régulation de la formation d'ostéoclastes
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
CA2441538A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
DE60235418D1 (de) 2001-04-03 2010-04-01 Nestle Sa Osteoprotegerin in Milch
TR201809678T4 (tr) * 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
EP1560843A4 (en) * 2002-01-04 2006-09-06 Xencor Inc NEW VARIANTS OF RANKL PROTEIN
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 tnf-펩티드의 담체 콘쥬게이트의 의학적 용도
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
WO2009154770A2 (en) * 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
US20250304708A1 (en) * 2022-09-07 2025-10-02 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin
KR20250118303A (ko) * 2024-01-29 2025-08-06 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE4496393T1 (de) 1993-08-27 1996-11-21 Dow Chemical Co Verfahren zur Trennung von Enantiomeren
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
EE200100149A (et) 2002-08-15
NO20011304D0 (no) 2001-03-14
IL141588A (en) 2008-07-08
CN1318105A (zh) 2001-10-17
IL141588A0 (en) 2002-03-10
TR200100737T2 (tr) 2001-07-23
PT1114166E (pt) 2005-08-31
AU754971B2 (en) 2002-11-28
HRP20010188A2 (en) 2002-04-30
DE69924392D1 (de) 2005-04-28
DE69924392T2 (de) 2006-03-09
WO2000015807A1 (en) 2000-03-23
SK3062001A3 (en) 2002-02-05
EP1114166A1 (en) 2001-07-11
KR20010085807A (ko) 2001-09-07
CA2343654A1 (en) 2000-03-23
AU5617399A (en) 2000-04-03
KR100671036B1 (ko) 2007-01-18
PL346698A1 (en) 2002-02-25
CZ2001789A3 (cs) 2001-08-15
US20040115199A1 (en) 2004-06-17
ID28386A (id) 2001-05-17
EP1114166B1 (en) 2005-03-23
ATE291628T1 (de) 2005-04-15
JP2002525060A (ja) 2002-08-13
HK1040261A1 (zh) 2002-05-31
NO20011304L (no) 2001-05-15
US6645500B1 (en) 2003-11-11
HUP0103578A2 (hu) 2002-01-28
ES2239457T3 (es) 2005-09-16
PL196790B1 (pl) 2008-01-31
NZ510508A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
AU2869799A (en) Diagnostic method for analyzing emboli
HUP0103625A3 (en) Method for regenerating catalysts
IL122597A0 (en) System and method for monitoring activity
AU2001271066A1 (en) Method for screening ligand having biological activity
GB9809414D0 (en) Method
IL145786A0 (en) Method for down-regulating il5 activity
IL138753A0 (en) Method and arrangement for taking up apertures
IL140951A0 (en) Method for analyzing cuts
GB2332596A9 (en) Method for predicting interference
GB2345776B (en) Method for interpreting petrophysical data
GB2361101B (en) Data analysis
GB9819764D0 (en) Method
GB9814055D0 (en) Method
SI1114166T1 (en) Method for down-regulating osteoprotegerin ligand activity
GB9819769D0 (en) Method
GB9802475D0 (en) Method
GB9824321D0 (en) Method
GB9820988D0 (en) Screening method
GB2336506B (en) Method and system for interference reduction
GB9821225D0 (en) Method
GB9820185D0 (en) Method
IL140058A0 (en) Methods for inhibiting tef-3 activity
GB0026109D0 (en) An analysis method
GB9809782D0 (en) Method
GB9825374D0 (en) Method

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees